Key result
High levels of plasma microparticles are associated with chronic inflammation, endothelial damage, and thrombosis, emerging as key players and potential biomarkers in cardiovascular diseases.
Why the study?
Microparticles play key roles in cardiovascular disease and act as biomarkers, but their clinical application remains limited despite improving detection methods.
Microparticles are emerging as significant modulators and potential biomarkers in cardiovascular diseases, linked to inflammation, endothelial damage, and thrombosis.
Microparticles merit prospective validation before biomarker use; leaves open their clinical adoption in cardiovascular risk stratification.
Microparticles are a distinctive group of small vesicles, without nucleus, which are involved as significant modulators in several physiological and pathophysiological mechanisms. Plasma microparticles from various cellular lines have been subject of research. Data suggest that they are key players in development and manifestation of cardiovascular diseases and their presence, in high levels, is associated with chronic inflammation, endothelial damage and thrombosis. The strong correlation of microparticle levels with several outcomes in cardiovascular diseases has led to their utilization as biomarkers. Despite the limited clinical application at present, their significance emerges, mainly because their detection and enumeration methods are improving. This review article summarizes the evidence derived from research, related with the genesis and the function of microparticles in the presence of various cardiovascular risk factors and conditions. The current data provide a substrate for several theories of how microparticles influence various cellular mechanisms by transferring biological information.
No takes yet. Share an insight, caveat, or question.
Voukalis et al. (2019) conducted a review in cardiovascular diseases. Microparticles was evaluated. High levels of plasma microparticles are associated with chronic inflammation, endothelial damage, and thrombosis, emerging as key players and potential biomarkers in cardiovascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: